PDE5A and anemia (phenotype): Notably, the use of PAH-specific medications such phosphodiesterase type 5 (PDE5) inhibitors, endothelin receptor antagonists (ETRA), guanylate cyclase (GC) stimulators or prostacyclin analogs did not significantly impact on the frequency of anemia or ID in our patient cohort.